Belimumab has been studied in a limited number of SLE patients with renal syringe are provided at the end of the package leaflet (see Step-by-step. Learn about BENLYSTA (belimumab), an FDA-approved prescription infusion or self-injectable lupus medication to help treat your Request your FREE Info Kit. Keep in the original package until time of use to protect from light. Insert the entire Needle into the pinched area of the skin at a slight degree angle using a.
|Published (Last):||26 July 2015|
|PDF File Size:||3.50 Mb|
|ePub File Size:||14.94 Mb|
|Price:||Free* [*Free Regsitration Required]|
Make sure the gold needle guard is flat on the skin. Administration of belimumab requires an inserf clinician prepared to manage anaphylaxis and infusion-related reactions.
Discard any unused packahe solution that remains in the vials. Therefore, belimumab use belimumaab not recommended in combination with intravenous cyclophosphamide. Single-use vials of belimumab lyophilized powder for injection: Belimumab lnsert carries a risk of serious hypersensitivity reactions or anaphylaxis.
Reductions in naive and the SLE B-cell subset were observed as early as week 8 and were sustained to week Maternal antibodies are known to be present in human milk; however, data are limited regarding use of belimumab during breast-feeding, and belimumzb excretion in human milk is unknown.
Receipt of belimumab also led to reductions in IgG and anti-dsDNA and to increases in complement C3 and C4 as early as week 8 and were sustained through week When the injection is complete, lift the injector from the injection site. Patients may use the prefilled syringe or auto-injector after proper training. Advise patients and caregivers of the signs and symptoms of hypersensitivity and to seek immediate medical help if symptoms develop. Each 5-mL vial delivers mg of belimumab.
Consider the developmental and health benefits of breast-feeding and any potential adverse effects on the breastfed infant along with the mother’s clinical need for belimumab when considering belimumab therapy.
Benlysta (belimumab) dose, indications, adverse effects, interactions from
The clinical relevance of these effects on B cells has not been established. Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit. If a dose is missed, administer as soon as possible. Administer belimumab by intravenous infusion only; do not give as an IV push or bolus. Preparation of Solutions BENLYSTA is provided as a lyophilized powder in a single-use vial for intravenous infusion only and should be reconstituted gelimumab diluted by a healthcare professional using aseptic technique as follows: If transitioning from intravenous to subcutaneous therapy, administer the first subcutaneous dose 1 to 4 weeks after the last intravenous dose.
The infusions were administered at 2-week intervals for the first 3 doses and at 4-week iinsert thereafter. Therefore, belimumab use is not recommended in combination with TNF blockers. Memory cells increased initially and slowly declined toward baseline concentrations by week Adverse events associated with the infusion may also occur. Push the plunger all the way down until all of the solution is injected.
Serious reactions have been reported. Once reconstitution is complete, the solution should be opalescent and colorless to pale yellow, and without particles. Preparation for use of the prefilled syringe or auto-injector: Do not use beyond the expiration date. Reconstitution is typically complete within 10 to 15 minutes after the sterile water has been added, but it may take up to 30 minutes. Administration of IV infusion: The mechanism of action of belimumab could increase the risk for the development of malignancies.
Therefore, belimumab packagf is not recommended in combination with biologic therapies. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 60 seconds every 5 minutes until the powder is dissolved. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 60 seconds every 5 minutes until the powder is dissolved.
We do not record any personal information entered above. The needle will automatically rise up into the needle guard.
The injection may take up to 15 seconds to complete. Do not administer where skin is tender, bruised, erythematous, or hard. Exploratory sub-group analyses of response rates based on race were performed during clinical trials; some data suggest that Black patients may have reduced clinical response to belimumab. There were more deaths reported bwlimumab belimumab than with placebo during the controlled period of the clinical trials.
We’re strengthening digital security to protect you.
Do not warm in any other way. Live virus vaccines should generally not be administered to an immunosuppressed patient. Protect reconstituted solution from sunlight. Discontinue the infusion immediately if the patient experiences a serious hypersensitivity reaction. Only healthcare providers prepared to manage anaphylaxis should pafkage belimumab by infusion.